Оригинальные и генерические препараты в сфере оральной контрацепции

В. В. Каминский; М. Н. Шалько; Ю. С. Мудра

doi:10.18370/2309-4117.2016.28.46-50

Authors

В. В. Каминский National Medical Academy of Postgraduate Education named after P.L. Shupyk; Obstetrics and Gynecology at the Ministry of Health of Ukraine; Kyiv City Center for Reproductive and Perinatal Medicine, Ukraine
М. Н. Шалько National Medical Academy of Postgraduate Education named after P.L. Shupyk; Kyiv City Center for Reproductive and Perinatal Medicine, Ukraine https://orcid.org/0000-0002-0302-9699
Ю. С. Мудра National Medical Academy of Postgraduate Education named after P.L. Shupyk, Ukraine https://orcid.org/0000-0002-4293-9353

DOI:

https://doi.org/10.18370/2309-4117.2016.28.46-50

Keywords:

original drug, generic, combined oral contraceptives, bioequivalence

Abstract

Generics drugs are increasingly found on the pharmacies shelves today. Authors of this article have tried to find an answer to some questions: what are generic drugs and which drugs should be used – the original or generic.

Original drug is first synthesized and passed a full cycle of pre-clinical and clinical trials for drugs, it having brand name and patented chemical formula. The formula of the original drug cannot be repeated during the whole period of patent protection – 20 years. After that any pharmaceutical company can begin to release their version of this drug – there are so-called generic drugs or generics. Generic product is a drug that has the same qualitative and quantitative composition of active substances and the same pharmaceutical form as the reference product, and whose bioequivalence reference product confirmed the relevant studies of bioavailability.

Generic effectiveness is associated with its bioavailability. Rate and extent of drug accumulation at the site of its intended action are quantitative characteristic determining bioavailability of drug. Bioavailability of the drug is concluded by drug concentration in the blood. If drugs have the same bioavailability in identical conditions, they are considered bioequivalent.

The effectiveness of generic must be evaluated not only on the basis of subjective feelings of patient and doctor, but first and foremost to achieving the targets of clinical results, objectively reflecting the effect of the drug. Interchangeability is possible only for generic authenticated on the pharmacokinetic and clinical equivalence of the original drug.

The presence in manufacturer a GMP certificate (Good Manufacturing Practice for Medicinal Products), which is regularly confirmed in the course of a full-scale test production makes it a great deal of confidence to talk about the quality of drug enterprise. Only generic that manufactured in compliance with all GMP rules and past bioequivalence study should be allowed for sale and can be safely administered to a patient by doctor.

Author Biographies

В. В. Каминский, National Medical Academy of Postgraduate Education named after P.L. Shupyk; Obstetrics and Gynecology at the Ministry of Health of Ukraine; Kyiv City Center for Reproductive and Perinatal Medicine

MD, professor, corresponding member of the NAMS of Ukraine, head of the Obstetrics, Gynecology and Reproductology Department; chief specialist; director

М. Н. Шалько, National Medical Academy of Postgraduate Education named after P.L. Shupyk; Kyiv City Center for Reproductive and Perinatal Medicine

PhD, assistant of the Obstetrics, Gynecology and Reproductology Department;

deputy director on the organizational and methodical work

Ю. С. Мудра, National Medical Academy of Postgraduate Education named after P.L. Shupyk

Obstetrician-gynecologist of the Obstetrics, Gynecology and Reproductology Department

References

Welage, L.S., Kirking, D.M., Ascione, F.J., Gaither, C.A. “Understanding the scientific issues embedded in the generic drug approval process.” J Am Pharm Assoc 41 (2001): 856–67.
Sergeeva, O. “American-Russian relations. Patients in the US are switching to generics, in Russia are still not.” Pharmaceutical Bulletin 27.559 (2009).
Maximov, M.L. “The choice between the original and generic products in everyday practice.” Medicine 1 (2012): 10–15.
Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending. “Bioequivalence between brand-name and generic OCs.” Contracept Rep 13.2 (2002): 6–9.
Directive 2001/83/EC on the Community code relating to medicinal products for human use.
Khoseva, E.N., Morozova, T.E. “Economic advantages and weaknesses of generic in the system of drug provision for population in Russia and abroad.” Qualitative Clinical Practice 2 (2013): 63–68.
U.S. Food and Drug Administration. Therapeutic equivalence of generic drugs. Letter to health practitioners. Rockville (MD). FDA (1998).
Rosenberg, M.J., Waugh, M.S. “Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons.” Am J Obstet Gynecol 179 (1998): 577–82.
Guidance on contraception. Ed. by prof. V.N. Prilepskaya. Moscow. MEDpress-Inform (2006): 400 p.
Yakovleva, T.B., Babenko, O.N., Pylypenko, O.N. “Premenstrual syndrome.” Medical Emergency Conditions 3.58 (2014): 159–63.
Schleussner, E., Michels, W., Bethge, S., Klinger, G. “Effect of dienogest on the hypothalamo, pituitary axis: A pilot study.” In: Dienogest. Preclinical and clinical Features of a Unique Progesteron, 2nd Edition. Ed. by A.T. Teichmann. Berlin. Walter de Gruyter (1995): 171–9.